Analysis of two pivotal Yescarta clinical trials revealed that patients' germline DNA influences both toxicity risk and CAR T expansion, opening new opportunities for smarter cell therapy design.
The rise of iPSC-derived immune cells and CRISPR-based engineering is reshaping functional genomics, but protein-level validation has struggled to keep pace.